The emergence of dual-action receptor agonists in the approach of type 2 diabetes and obesity has sparked considerable interest, particularly regarding retatrutide and tirzepatide. While both medications target both https://jimbhvd039951.vidublog.com/37656064/retatrutide-vs-tirzepatide-a-comparative-analysis